<p>Biosplice’s lorecivivint, which may slow rather than mask knee osteoarthritis, has entered formal review with UK’s MHRA ahead of EU filing. Ask anyone who’s watched a parent stop gardening, or gradually give up stairs, what osteoarthritis actually costs a person, and cartilage loss is rarely the fir</p>